Sugi Predict

Sugi Predict / Targets / PSMD3

PSMD3

26S proteasome non-ATPase regulatory subunit 3 · O43242 · PSMD3 on Sugi Atlas →

7,833 patent compounds predicted against PSMD3, 6,175 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1478606 SCHEMBL1478606 0.58 12/20
SCHEMBL607010 SCHEMBL607010 0.56 12/20
SCHEMBL608381 SCHEMBL608381 0.53 12/20
SCHEMBL606616 SCHEMBL606616 0.51 12/20
SCHEMBL1477637 SCHEMBL1477637 0.57 11/20
SCHEMBL607972 SCHEMBL607972 0.55 11/20
SCHEMBL608782 SCHEMBL608782 0.54 11/20
SCHEMBL609278 SCHEMBL609278 0.54 11/20
SCHEMBL607553 SCHEMBL607553 0.54 11/20
SCHEMBL605822 SCHEMBL605822 0.54 11/20
SCHEMBL606932 SCHEMBL606932 0.53 11/20
SCHEMBL1477893 SCHEMBL1477893 0.53 11/20
SCHEMBL608362 SCHEMBL608362 0.53 11/20
SCHEMBL608599 SCHEMBL608599 0.53 11/20
SCHEMBL1327441 SCHEMBL1327441 0.53 11/20
SCHEMBL605129 SCHEMBL605129 0.52 11/20
SCHEMBL608009 SCHEMBL608009 0.52 11/20
SCHEMBL1478157 SCHEMBL1478157 0.52 11/20
SCHEMBL609081 SCHEMBL609081 0.52 11/20
SCHEMBL606926 SCHEMBL606926 0.52 11/20

Clinical trials — most relevant to PSMD3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease PHASE4UNKNOWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Biologic Correlative Taxotere/AC PHASE2COMPLETED
Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors PHASE2COMPLETED
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer PHASE2COMPLETED
A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis PHASE1/PHASE2COMPLETED
Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma PHASE1COMPLETED
Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma PHASE1COMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Cardiovascular Complications of Carfilzomib Treatment nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment nanUNKNOWN
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Collection of Blood Samples for DNA in Motor Neuron Disease nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
Establishment of Human Cellular Disease Models for Wilson Disease nanCOMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Dysfunctions of Human Muscle Stem Cells in Sepsis nanCOMPLETED
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone. nanUNKNOWN
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq) nanRECRUITING
Implementation of Molecular Diagnostic Pathways nanUNKNOWN
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PSMD3 binder may also engage these)

ProteinNameSimilarity
Q2KJ46 — 1.000 Q2KJ46 →
P14685 — 1.000 P14685 →
Q06364 — 0.982 Q06364 →
Q5ZLA5 — 0.979 Q5ZLA5 →
P93768 — 0.979 P93768 →
Q6P0H6 — 0.977 Q6P0H6 →
Q3B8M3 — 0.976 Q3B8M3 →
AP2A1 AP-2 complex subunit alpha-1 0.975 landscape →
Q6DRI1 — 0.975 Q6DRI1 →
Q3SZA0 — 0.975 Q3SZA0 →
Q6P7L9 — 0.975 Q6P7L9 →
Q5R648 — 0.975 Q5R648 →
O88544 — 0.975 O88544 →
P17426 — 0.975 P17426 →
B5DGH9 — 0.974 B5DGH9 →
Q05AY2 — 0.973 Q05AY2 →
Q641X8 — 0.973 Q641X8 →
Q94899 — 0.972 Q94899 →
Q68FS2 — 0.972 Q68FS2 →
Q4R5E6 — 0.972 Q4R5E6 →
A7Y521 — 0.972 A7Y521 →
Q5R8K9 — 0.971 Q5R8K9 →
Q4R6G8 — 0.971 Q4R6G8 →
P60229 — 0.971 P60229 →
COPS4 COP9 signalosome complex subunit 4 0.971 landscape →
Q3T102 — 0.970 Q3T102 →
F1QGH9 — 0.969 F1QGH9 →
Q5E964 — 0.968 Q5E964 →
EIF3E Eukaryotic translation initiation factor 3 subunit E 0.968 landscape →
Q5ZIA5 — 0.966 Q5ZIA5 →